Floatz logo

ANTI-PD-1/TIM-3 BISPECIFIC ANTIBODY RO7121661

Non-Small Cell Lung Carcinoma

Hoffmann-La Rochemonoclonal_antibodyPhase 1Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
73/ 100

Competitive context

1206 Active assets in the Non-Small Cell Lung Carcinoma cohort.

Asset / SponsorPhaseRating
Zorifertinib
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3BBB
Necitumumab
Jonsson Comprehensive Cancer Center
Phase 3BBB
Glumetinib
Shanghai JMT-Bio Inc.
Phase 3BBB
Onartuzumab
Hoffmann-La Roche
Phase 3BBB
Veliparib
AbbVie
Phase 3BBB

View all 50 →

Same molecule, other indications

ANTI-PD-1/TIM-3 BISPECIFIC ANTIBODY RO7121661 is also rated in:

esophageal squamous cell carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
small cell lung carcinomaDormant
CC
Indicative ·
44 / 100
View asset →
metastatic melanomaDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →